Haiyan Wang

Prof. Dr. Haiyan Wang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
QGQiaoyun Gong
Qiaoyun Gong
RZRulin Zhang
Rulin Zhang
FWFang Wei
Fang Wei
JFJunwei Fang
Junwei Fang
JZJingfa Zhang
Jingfa Zhang
HWHaiyan Wang
Haiyan Wang
Empagliflozin (EMPA) is the first sodium-glucose co-transporter 2 inhibitor to significantly reduce cardiovascular and kidney complications in type 2 diabetes mellitus. Given this, we speculate that EMPA may have the potential to intervene in diabetic retinopathy (DR), which is another diabetes-specific microvascular complication. Db/db mice were treated with EMPA for different periods to observe the retinas and related mechanisms. EMPA effectively balanced body weight and blood glucose levels, mitigated ocular edema and microaneurysm in db/db mice. EMPA significantly inhibited oxidative stress, apoptosis and recovered tight junction in diabetic retinas. MS/MS analyses showed that EMPA suppressed aberrant branched-chain amino acid (BCAAs) accumulation in db/db retinas, which led to the inhibition of the mammalian target of rapamycin activation, downregulation of inflammation, and angiogenic factors, including TNF-ɑ, IL-6, VCAM-1, and VEGF induced by diabetes. Furthermore, branched-chain α-keto acids (BCKAs), which are catabolites of BCAAs, were increased in diabetic retinas and decreased with EMPA application. Moreover, branched-chain ketoacid dehydrogenase kinase (BCKDK) was enhanced, BCKDHA and BCKDHB were decreased in diabetic retinas. This could be reversed by EMPA treatment, thus promoting BCAAs catabolism to decrease BCAAs and BCKAs accumulation in diabetic retinas. The high levels of BCAAs in the plasma and enhanced L-type amino acid transporter 1 (LAT1) were responsible for the high levels of BCAAs in diabetic retinas, which could be inhibited by EMPA. Overall, EMPA could ameliorate DR manifestations. The normalization of BCAAs catabolism and intake may play a role in this process. This study supports EMPA as a protective drug against DR.

16 August 2024 in Acta Diabetologica
Verified
Journal Article
Open access
PDF file
QGQiaoyun Gong
Qiaoyun Gong
JWJingyi Wang
Jingyi Wang
DLDawei Luo
Dawei Luo
YXYupeng Xu
Yupeng Xu
RZRulin Zhang
Rulin Zhang
HWHaiyan Wang
Haiyan Wang
Aims: This study aimed to investigate branched-chain amino acid (BCAA) catabolism in diabetic retinopathy (DR). Methods: Wild-type and db/db mice were fed BCAAs (5 or 10 mg/kg/day) for 12 weeks, and hyperglycemia-exposed Müller cells were treated with BCAAs (2 or 5 mmol/L) for 24 and 48 h. BCAA levels were measured using MS/MS. Western blotting was performed to detect proteins. Flow cytometry, oxygen consumption rate, and Cell Counting Kit-8 assays were used to evaluate Müller cell viability. Each experiment was conducted at least thrice. Results: BCAAs and branched-chain α-keto acids (BCKAs) were increased in the retina and systemic tissues of diabetic mice, and these changes were further enhanced to approximately 2-fold by extra BCAAs compared to wild-type group. In vitro, BCAAs and BCKAs were induced in hyperglycemic Müller cells, and augmented by BCAA supplementation. The aberrant BCAA catabolism was accompanied by mTORC1 activation and subsequently induced TNF-ɑ, VEGFA, GS, and GFAP in retinas and Müller cells under diabetic conditions. The cell apoptosis rate increased by approximately 50%, and mitochondrial respiration was inhibited by hyperglycemia and BCAA in Müller cells. Additionally, mTORC1 signaling was activated by leucine in Müller cells. Knockdown of Sestrin2 or LeuRS significantly abolished the leucine-induced mTORC1 phosphorylation and protected Müller cell viability under diabetic conditions. Conclusions: We found that BCAA catabolism is hindered in DR through mTORC1 activation. Leucine plays a key role in inducing mTORC1 by sensing Sestrin2 in Müller cells. Targeting Sestrin2 may ameliorate the toxic effects of BCAA accumulation on Müller cells in DR.

2 June 2025 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
JWJingyi Wang
Jingyi Wang
ZYZihan Yin
Zihan Yin
JYJingxiao Yang
Jingxiao Yang
SSSijun Sun
Sijun Sun
XTXiaofang Tang
Xiaofang Tang
HWHaiyan Wang
Haiyan Wang
To investigate how branched-chain amino acid (BCAA) metabolism is remodeled and to determine its contribution to diabetic retinopathy progression. We analyzed Bcat1 and Bcat2 expression in the retina using single-cell sequencing data and immunofluorescence. Bcat1-mediated remodeling of BCAA metabolism was assessed via targeted metabolomics in Müller cells. We performed chromatin immunoprecipitation (ChIP) to examine histone methylation at inflammatory gene promoters. Additionally, we utilized RNA sequencing and kinase screening assays to delineate phosphorylation regulation of Bcat1 activity. In vivo, we established diabetic mouse models and treated them with Bcat1-specific inhibitor to evaluate retinal inflammation and vascular leakage. Bcat1 was predominantly expressed in Müller cells and exhibited increased activity under diabetic conditions, leading to a remodeling of BCAA catabolism and upregulation of inflammatory genes (interleukin 6 [Il6] and tumor necrosis factor-α [Tnf-α]). Bcat1 activity was negatively regulated by polo-like kinase 4 (Plk4)-mediated phosphorylation at threonine 333. In high glucose-treated Müller cells, elevated Bcat1 activity reduced α-ketoglutarate (α-KG), a critical substrate for histone demethylation reactions, resulting in higher histone H3 lysine 4 trimethylation (H3K4me3) levels at inflammatory gene promoters, and further boosted retinal inflammation. Treatment with chemical Bcat1 inhibitors (BAY-069 and ERG240) significantly reduced inflammatory gene expression and vascular leakage in diabetic retinas in vivo. Bcat1 activation mediates BCAA metabolism remodeling in Müller cells and epigenetically induces retinal inflammation, which offers a potential therapeutic target for diabetic retinopathy. Diabetes and diabetic retinopathy are potentially driven not only by hyperglycemia but also by dysregulated amino acid metabolism.

5 June 2024 in Journal of Proteome Research
Verified
Journal Article
Open access
QGQiaoyun Gong
Qiaoyun Gong
MFMingshui Fu
Mingshui Fu
JWJingyi Wang
Jingyi Wang
SZShuzhi Zhao
Shuzhi Zhao
HWHaiyan Wang
Haiyan Wang
Primary acute angle-closure glaucoma (PAACG) is a sight-threatening condition that can lead to blindness. With the increasing incidence of COVID-19, a multitude of people are experiencing acute vision loss and severe swelling of the eyes and head. These patients were then diagnosed with acute angle closure, with or without a history of PACG. However, the mechanism by which viral infection causes PACG has not been clarified. This is the first study to explore the specific inflammatory proteomic landscape in SARS-CoV-2-induced PAACG. The expression of 92 inflammation-related proteins in 19 aqueous humor samples from PAACGs or cataract patients was detected using the Olink Target 96 Inflammation Panel based on a highly sensitive and specific proximity extension assay technology. The results showed that 76 proteins were significantly more abundant in the PAACG group than in the cataract group. Notably, the top eight differentially expressed proteins were IL-8, MCP-1, TNFRSF9, DNER, CCL4, Flt3L, CXCL10, and CD40. Generally, immune markers are related to inflammation, macrophage activation, and viral infection, revealing the crucial role of macrophages in the occurrence of PAACGs caused by SARS-CoV-2.

27 October 2025 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
YXYupeng Xu
Yupeng Xu
ZYZihan Yin
Zihan Yin
QGQiaoyun Gong
Qiaoyun Gong
MZMingjie Zhu
Mingjie Zhu
CLChuming Lu
Chuming Lu
HWHaiyan Wang
Haiyan Wang
Background: To examine the association between estimated pulse wave velocity (ePWV), a marker of arterial stiffness, and glaucoma incidence in Chinese cohort, highlighting ePWV’s potential as a scalable population-level risk factor for glaucoma screening. Materials and methods: Data were obtained from the China Health and Retirement Longitudinal Study (CHARLS). A total of 11,968 adults aged ≥45 years without glaucoma at baseline (2011–2018) were followed for up to 7 years ePWV was calculated from age and blood pressure and divided into quartiles. Cox proportional hazards models assessed risk, while restricted cubic spline and two-piecewise models explored dose–response patterns. Subgroup analyses tested effect modification by demographic and lifestyle factors. Results: During a 7-year follow-up, participants in the highest ePWV quartile (≥10.58 m/s) had a higher risk of glaucoma compared with the lowest quartile (<8.01 m/s) (HR [hazard ratio] 1.39, 95% CI [confidence interval] 1.00–1.93). Each 1 m/s increase in ePWV was associated with a 7% higher glaucoma risk (HR 1.07, 95% CI 1.01–1.13). The dose response relationship was linear without evidence of a threshold. Associations were consistent across most subgroups. Sensitivity analyses showed that ePWV was a stronger predictor of glaucoma than age or blood pressure alone. Conclusion: Higher ePWV independently links to greater glaucoma risk in middle-aged and older Chinese. This observed association indicates that ePWV provides incremental predictive value beyond traditional demographic or clinical factors. Building on this characteristic, incorporating ePWV into future artificial intelligence (AI)-enabled glaucoma screening models may potentially contribute to improving risk-stratification accuracy and facilitating early identification of high-risk individuals.

5 March 2026 in iScience
Verified
Journal Article
Open access
XLXin Liang
Xin Liang
NLNing Li
Ning Li
QGQiaoyun Gong
Qiaoyun Gong
HWHaiyan Wang
Haiyan Wang
Steroid-induced glaucoma (SIG) is the most common form of secondary glaucoma and is characterized by trabecular meshwork dysfunction and elevated intraocular pressure. Here, we investigated the contribution of trabecular meshwork cell (TMC) apoptosis to SIG pathogenesis using both in vivo and in vitro models. In a rat SIG model, reduced TMC density and increased apoptosis were observed. Integrated transcriptomic and proteomic analyses identified reduced peroxisome proliferator-activated receptor-γ (PPAR-γ) expression in SIG TMCs, which was validated by immunohistochemistry and immunoblotting. Functional enhancement of PPAR-γ attenuated TMC apoptosis and suppressed the activation of the NF-κB/Bax/Bcl-2/caspase-3 signaling pathway. Mechanistically, optineurin (OPTN) was identified as a downstream target of PPAR-γ, with PPAR-γ directly binding to the OPTN promoter to regulate its transcription. Genetic disruption of OPTN diminished the protective effects of PPAR-γ. In vivo modulation of the PPAR-γ/OPTN axis alleviated trabecular meshwork injury, reduced apoptosis, and lowered intraocular pressure, highlighting a regulatory pathway linked to SIG progression.